Global Superbug Pipeline Shrinks by 35% as Death Toll Projected to Double by 2050

The Race Against Superbugs Is Being Lost, Experts Warn

The world's ability to combat drug-resistant infections is deteriorating at an alarming pace. A new report has revealed that the pipeline of new antimicrobial drugs has contracted by 35% over the past five years, dropping from 92 medicines in development to just 60. Experts are sounding the alarm, warning that unless the pharmaceutical industry dramatically increases its investment, deaths linked to drug-resistant infections could double to 8 million annually by 2050.

The findings come from the Access to Medicine Foundation (AMF), a Netherlands-based nonprofit supported by the Wellcome Trust, which assessed the antimicrobial research efforts of 25 companies worldwide.

A Dangerously Thin Development Pipeline

"Overall, the research and development pipeline remains worryingly thin, and industry investment has lost momentum," said Jayasree K Iyer, the AMF's chief executive. She went further, describing antimicrobial resistance as the single greatest threat facing global healthcare today.

Particularly concerning is the near-absence of medicines being developed for young children. Only five drugs are currently in development for children under the age of five — a demographic that is disproportionately vulnerable to life-threatening infections.

The Fleming Initiative, named after Scottish physician Alexander Fleming who famously discovered penicillin in London nearly a century ago, has projected an even grimmer outcome, estimating that drug-resistant infections could claim up to 10 million lives annually by 2050.

Big Pharma Steps Back from Antibiotic Research

Cancer surgeon and NHS investigator Lord Ara Darzi, who serves as executive chair of the Fleming Initiative, underscored the moral dimension of the crisis. He noted that infection is the second-leading cause of death among cancer patients, stating that pharmaceutical companies carry a "moral responsibility in underwriting the risk" of antimicrobial research.

"New therapies mean cancer can be fought, but then sadly patients succumb to an infection that was treatable a decade ago," Lord Darzi said at the AMF report launch. Drawing on a sports analogy, he added: "You don't win a game if you have three good strikers and your defence is weak."

Of the large pharmaceutical companies still active in this space, the UK's GSK leads the field with 30 active antimicrobial projects. It is joined by Japan's Shionogi and Otsuka as the only major players continuing to invest meaningfully in this area. Notably, US giant Pfizer, which shared the top position with GSK in 2021, has significantly scaled back its efforts.

Britain's largest pharmaceutical company, AstraZeneca, does not feature in the rankings at all, as infectious disease research has never been a core focus of its business and it currently holds no antibiotic portfolio.

Resistance Is Outpacing Research

Claudia Martínez, AMF's director of research, was blunt in her assessment: "We don't have enough research going into antimicrobials to outpace resistance."

Data from the World Health Organization paints a stark picture of just how rapidly the situation is worsening. In 2023, one in six laboratory-confirmed bacterial infections showed resistance to antibiotic treatments. More troublingly, over 40% of antibiotics lost effectiveness against common blood, gut, urinary tract, and sexually transmitted infections between 2018 and 2023.

Hospitals around the world have reported a sharp rise in previously manageable infections that no longer respond to standard treatments.

Low-Income Countries Bear the Heaviest Burden

People living in low- and middle-income countries, where infectious diseases already cause the most harm, face the greatest risk from drug-resistant superbugs. The AMF report emphasizes the urgency of action, with Iyer stating plainly: "There is no time to lose."

Beyond drug development, experts stress that curbing the overuse of antibiotics — particularly in food production — and managing antibiotic waste responsibly are equally critical steps in slowing the spread of resistance.

Rethinking the Economics of Antibiotic Development

A fundamental challenge in addressing this crisis is economic. The market for new antibiotics is simply not profitable enough to attract widespread pharmaceutical investment. John-Arne Røttingen, chief executive of the Wellcome Trust, acknowledged that the shortage of effective antibiotics represents a "big challenge for society."

To address the financial disincentive, the European Commission is exploring the introduction of transferable exclusivity vouchers, which would grant developers of new antimicrobial drugs an additional 12 months of data protection — effectively extending their period of market exclusivity.

Røttingen also advocated for the wider adoption of the NHS's subscription-based model for antibiotics, which provides pharmaceutical companies with a guaranteed revenue stream regardless of sales volume. He argued that other high-income nations should implement similar systems to make antimicrobial development a more viable commercial pursuit.

A Window of Opportunity

Despite the bleak outlook, AMF's Iyer pointed to three recently approved antibiotics and seven additional promising medicines currently in late-stage development as evidence that progress is achievable. "It is possible to tilt the battle against superbugs in humanity's favour," she said — but only if the pharmaceutical industry, governments, and international bodies act with far greater urgency than they have so far.